Rinsho Shinkeigaku (Clinical Neurology)

Case Report

A case of the successful treatment of severe myoclonus with Lance-Adams syndrome by add-on perampanel showing long term effects

Kazuyuki Saito, M.D., Ph.D.1), Kazuki Oi, M.D.2), Akira Inaba, M.D., Ph.D.3), Masaki Kobayashi, M.D., Ph.D.1), Akio Ikeda, M.D., Ph.D.2) and Yoshiaki Wada, M.D., Ph.D.1)

1) Department of Neurology, Nissan Tamagawa Hospital
2) Department of Epilepsy, Movement Disorders and Physiology, Kyoto University Graduate School of Medicine
3) Department of Neurology, Kanto Chuo Hospital

Perampanel is an α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist that has been marked as an antiepileptic drug for partial-onset and primary generalized tonic-clonic seizures. There have been some recent reports of perampanel being effective against cortical myoclonus by Lafora disease and Unverricht-Lundborg disease. We herein report a 49-year-old man who presented with myoclonus due to Lance-Adams syndrome (LAS) after cardiopulmonary arrest caused by a severe bronchial asthma attack. Perampanel was very effective against myoclonus induced by LAS even in the chronic state, over 10 years after the remote onset. Perampanel should be considered for the treatment of extremely refractory myoclonus due to LAS.
Full Text of this Article in Japanese PDF (6510K) @@@@ Full Text of this Article in English HTML

(CLINICA NEUROL, 61: 18|23, 2021)
key words: perampanel, Lance-Adams syndrome, myoclonus, anti-epileptogenic drugs

(Received: 17-May-20)